New and emerging targeted treatments in advanced non-small-cell lung cancer

Summary Targeted therapies are substantially changing the management of lung cancers. These treatments include drugs that target driver mutations, those that target presumed important molecules in cancer cell proliferation and survival, and those that inhibit immune checkpoint molecules. This area o...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2016-09, Vol.388 (10048), p.1012-1024
Main Authors: Hirsch, Fred R, Prof, Suda, Kenichi, MD, Wiens, Jacinta, PhD, Bunn, Paul A, MD
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Cancer therapies
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Chemotherapy
Clinical Trials as Topic
Cytotoxicity
Humans
Internal Medicine
Kinases
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Medical research
Molecular Targeted Therapy
Mutation
Patients
Protein-Tyrosine Kinases - genetics
Proto-Oncogene Proteins - genetics
Receptor Protein-Tyrosine Kinases - genetics
Receptor, Epidermal Growth Factor - genetics
Translocation, Genetic
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Targeted therapies are substantially changing the management of lung cancers. These treatments include drugs that target driver mutations, those that target presumed important molecules in cancer cell proliferation and survival, and those that inhibit immune checkpoint molecules. This area of research progresses day by day, with novel target discoveries, novel drug development, and use of novel combination treatments. Researchers and clinicians have also extensively investigated the predictive biomarkers and the molecular mechanisms underlying inherent or acquired resistance to these targeted therapies. We review recent progress in the development of targeted treatments for patients with advanced non-small-cell lung cancer, especially focusing on data from published clinical trials.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(16)31473-8